Shop Now Contact

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody

Cat # Size Price Quantity
5140011 mg$1750
5140025 mg$5950
51400325 mg$17850

  Bulk/Custom

Product Details

CloneRMP1-14 / B20-4.1.1
ApplicationFunctional assay, Neutralization, animal model study
Host SpeciesCHO cells
ReactivityMouse
FormatLiquid
Target NamePD1, PD-1, PDCD1, CD279, SLEB2, Vascular endothelial growth factor, VEGF-A, VEGFA, VEGF
Product DescriptionIn Vivo Grade Recombinant Anti-mouse PD-1 / VEGF-A Bispecific Antibody
IsotypeMouse IgG2c LALAPG Kappa
Antibody TypeRecombinant
Regulatory StatusRUO
Purity>95% by reducing SDS-PAGE
Endotoxin< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions4ºC
GradeIn vivo
Recommended UsageThis product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
Research AreasImmune Checkpoints, Activated T cells, Cancer Immunology, Tregs, Tfh cells, Activated B cells
See All FormatsClone RMP1-14 / B20-4.1.1

Background Information

Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor expressed primarily on activated T cells, B cells, and some myeloid cells. It plays a key role in maintaining immune tolerance by downregulating T cell activation when engaged by its ligands PD-L1 or PD-L2 on antigen-presenting cells or tumor cells. Structurally, PD-1 is a type I transmembrane glycoprotein composed of an extracellular immunoglobulin-like domain, a transmembrane region, and an intracellular tail containing immunoreceptor tyrosine-based inhibitory (ITIM) and switch motifs (ITSM). When PD-1 binds to PD-L1 or PD-L2, it initiates inhibitory signaling through SHP-2 phosphatase recruitment, dampening T cell proliferation, cytokine production, and cytotoxic function. In cancer, chronic PD-1 engagement leads to T cell exhaustion, allowing tumor cells to escape immune destruction. This has made PD-1 a central therapeutic target in immuno-oncology, giving rise to checkpoint inhibitors like pembrolizumab and nivolumab.

Vascular Endothelial Growth Factor A (VEGF-A) is a fundamental regulator of angiogenesis, promoting endothelial cell proliferation, migration, and vascular permeability. It binds to tyrosine kinase receptors VEGFR-1 and VEGFR-2 on endothelial cells, driving new blood vessel formation under physiological conditions such as wound healing and tissue repair. In cancer, VEGF-A is frequently overexpressed, leading to aberrant, leaky, and immunosuppressive vasculature that supports tumor growth and hinders immune cell infiltration. By sustaining hypoxic and immunosuppressive microenvironments, VEGF-A contributes not only to tumor progression but also to resistance against immune checkpoint blockade.

A bispecific antibody targeting PD-1 and VEGF-A offers a powerful strategy to simultaneously reinvigorate exhausted T cells and normalize the tumor vasculature. Dual blockade can act synergistically: inhibition of VEGF-A enhances immune cell infiltration by improving vessel structure and reducing hypoxia, while PD-1 blockade restores effector T cell function and anti-tumor immunity. This combination addresses two critical barriers to effective cancer immunotherapy: immune suppression and poor immune access to tumors. Moreover, delivering both mechanisms in a single bispecific antibody may optimize pharmacokinetics, improve co-localization within the tumor microenvironment, and reduce systemic toxicity compared with separate therapies. Preclinical and early clinical studies suggest that PD-1 × VEGF-A bispecifics could yield superior efficacy in “cold” tumors that respond poorly to checkpoint inhibitors alone by converting them into “hot,” inflamed microenvironments more amenable to immune attack. Thus, such bispecifics represent a rational evolution in cancer immunotherapy, bridging vascular and immune modulation for more durable anti-tumor responses.

Data Sheets

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody TDS

Related Products

In Vivo Star Anti-Mouse CD279 (PD1) / VEGF-A Bispecific Antibody, Clone 29F.1A12 / B20-4.1.1

Anti-Human VEGF (Aflibercept Biosimilar), Clone Aflibercept

Anti-Human VEGF (Bevacizumab Biosimilar), Clone Bevacizumab

Anti-Human VEGF-A (Brolucizumab Biosimilar), Clone Brolucizumab

Anti-Human PD1 (Camrelizumab Biosimilar), Clone Camrelizumab

Anti-Human PD1 (Cemiplimab Biosimilar), Clone Cemiplimab

Anti-Human PD1 (Nivolumab Biosimilar), Clone Nivolumab

Anti-Human PD1 (Pembrolizumab Biosimilar), Clone Pembrolizumab

Anti-Human VEGF (Fab) (Ranibizumab Biosimilar), Clone Ranibizumab

Anti-Human PD1 (Spartalizumab Biosimilar), Clone Spartalizumab

Frequently Asked Questions

What are In Vivo Star Biofunctional Antibodies?
In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.
How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?
Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.
What endotoxin and purity specifications do these antibodies meet?
All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.
Are these antibodies azide-free and carrier-free?
All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.
Do you provide isotype controls?
Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.
How should In Vivo Star antibodies be stored and handled?
Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.